Skip to content

To assess and compare the analgesic effect of intravenous Dexmedetomidine versus intraperitoneal Dexmedetomidine as an adjuvant to intraperitoneal Bupivacaine(0.125%) in laparoscopic cholecystectomy cases

Analgesic effect of intravenous versus intraperitoneal Dexmedetomidine as an adjuvant to intraperitoneal Bupivacaine(0.125%) in laparoscopic cholecystectomy cases:A Randomized Double Blind Interventional Study at SMS Hospital Jaipur during 2020-2021

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/02/040024
Enrollment
92
Registered
2022-02-04
Start date
Unknown
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K801- Calculus of gallbladder with othercholecystitis

Interventions

Intervention1: Inj dexmedetomidine 1microgram/kg intravenously: Inj dexmedetomidine 1microgram /kg diluted to 30 ml NS Intravenous ,over 10 minutes and 40 ml of 0.125% bupivacaine intraperitoneal afte

Sponsors

Sawai Man Singh Medical College and Attached Hospitals
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA GRADE 1 and 2 Weight (40-75)KG Patients undergoing laparoscopic cholecystectomy under general anaesthesia

Exclusion criteria

Exclusion criteria: 1. Patients not willing to participate in study 2. History of allergy to study drugs 3. BMI >30 kg/m2 4. Patients having renal or hepatic insufficiency, neurologic and psychiatric disease 5. Preoperative heart rate 6. Patients on antihypertensive medication with any alpha 2 adrenergic agonist e.g clonidine 7. If laparoscopic cholecystectomy converted to open cholecystectomy

Design outcomes

Primary

MeasureTime frame
1 To determine the difference in mean time duration for need of first rescue analgesia 2 To determine total consumption of analgesic in first 24 hourTimepoint: 24 hour

Secondary

MeasureTime frame
1 To determine difference in VAS score, sedation score at 30 min,1,2,4,6,12,24 hour 2 To determine difference in proportion of cases who develop side effectsTimepoint: 24 hour

Countries

India

Contacts

Public ContactDr Shailja Kumari

Sawai Man Singh Medical College and Attached Hospitals

Raghuvanshichitra@gmail.com09166609479

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026